Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.38 |
| ▸ | PTGFR | P43088 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758710 | 0.82 | SMN1; SMN2 (0.46) | ALDH1A1HPGDHSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL30744788 | 0.80 | ALOX15 (0.56) | ALOX15MGAMALDH1A1HPGDHSD17B10 | |
| SCHEMBL23723083 | 0.75 | BACE1 (0.58) | ALOX15MGAMALDH1A1HPGDHSD17B10 | |
| SCHEMBL25249069 | 0.72 | ALOX15 (0.50) | ALOX15MGAMALDH1A1HPGDHSD17B10 | |
| Transtorine SCHEMBL17596601 | 0.71 | ALOX15 (0.60) | ALOX15MGAMALDH1A1HPGDHSD17B10 | |
| SCHEMBL69125 | 0.71 | KDM4E (0.64) | ALOX15MGAMALDH1A1HPGDHSD17B10 | |
| SCHEMBL29450085 | 0.71 | KDM4E (0.64) | ALOX15MGAMALDH1A1HPGDHSD17B10 | |
| Transtorine SCHEMBL22979 | 0.71 | ALOX15 (0.60) | ALOX15MGAMALDH1A1HPGDHSD17B10 | |
| SCHEMBL837668 | 0.69 | ALOX15 (0.58) | ALOX15MGAMALDH1A1HPGDHSD17B10 | |
| SCHEMBL14578175 | 0.69 | ALOX15 (0.58) | ALOX15MGAMALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241138-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | PFAHL MAGNUS | 2006-10-26 | — | — | US | disclosed |
| US-7102000-B2 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1487443-A4 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1487443-A1 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | Incyte San Diego Incorporated (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003075924-A1 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241138-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | HDAC5, KAT5, IGFBP5 | ALOX15 1310/4885MGAM 2833/4885ALDH1A1 1489/4885 |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | GCKR, HDAC5, GPR119 | ALOX15 1096/4885MGAM 2197/4885ALDH1A1 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.